Request the brochure

* Denotes Required Field


Theme: Drug Development in the Era of Precision Medicine

5th Precision Medicine and Immuno-Oncology (PMIO) China Summit 2023 returns on September 7-8 in Shanghai as a premier precision medicine event in China. With the theme on Drug Development in the Era of Precision Medicine, PMIO China 2023 is committed to working with senior leaders and scientists across pharma, biotech and academia to continue driving innovation and advancement in the precision medicine ecosystem in China.

PMIO China 2023 aims to explore the major topics and cases studies on Trends in Innovative Drug Development in China, Small Molecule Drugs for Cancer Immunotherapy, Clinical Trial Design in the era of Precision Medicine, Advances in Liquid Biopsy Validation, ctDNA and Minimal Residual Disease (MRD) in Solid Tumors, Biomarkers and CDx, Multi-Omics Modalities Supporting Clinical Translation, New Drug Development in CNS and Metabolic Disorders , AI in Small-molecule Drug Discovery, Applications of Cryo-EM in Small Molecule Drug Design etc.

Whether working in Oncology, Neuroscience, NASH, Diabetes or cardiovascular diseases, come and join PMIO China 2023 with 800+ Drug Discovery, Clinical Biomarkers, Translational Medicine, Precision Medicine & Companion Diagnostics Directors, Heads and VPs together with biomarker and CDx solution providers, and diverse industry stakeholders. You cannot afford to miss this crucial China’s precision medicine industry event in 2023. Read more…
 

Snapshot of PMIO 2023

  • Precision Medicine and Cancer Immunology in China
  • Clinical Development of Immuno-Oncology in China
  • China-initiated Global Drug Development: Lessons Learned and Future Prospectus
  • Small-Molecule Immuno-Oncology Therapy: Advances, Challenges and New Directions
  • AI in small-molecule drug discovery: a coming wave?
  • Biomarker Discovery using Single Cell Technology
  • Multi-omics Technologies to Support Biomarker Discovery & Clinical Trial Execution
  • Streamlining Co-development of Drug-Dx in the Clinic
  • Challenges and Opportunities to Execute the Biomarker-Driven Clinical Trials
  • Liquid Biopsies in Cancer Drug Development & Clinical Use
  • ct-DNA and MRD in Solid Tumors: Current Horizons and Future Perspectives
  • Leveraging Machine Learning & AI in Translational Medicine
 

Event Features

  • 800+ Attendees, 200+ Companies, 50+ Speakers
  • 100+ attending organizations covering drug developers, Dx labs and CROs
  • 100+ KOLs and potential collaborators under ONE roof across 2 days
  • 70% on average attendees from primary market (pharma/biotech, research institutes, central labs etc.)
  • 60%+ attendees at company decision making and director level
  • 2 conferences at 1 location with 8 focused streams
Produced by
Endorsers
Media Partners